Portal de investigación
ESTUDIO DE FASE 3, ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, EN EL QUE SE EVALÚA LA EFICACIA Y SEGURIDAD DE IDELALISIB EN COMBINACIÓN CON BENDAMUSTINA Y RITUXIMAB, EN PACIENTES CON LEUCEMIA LINFOCÍTICA CRÓNICA PREVIAMENTE SIN TRATAR.
Datos básicos
- Código:
- GS-US-312-0123
- Protocolo:
- GS-US-312-0123
- EUDRACT:
- 2013-003313-17
- NCT:
- Centro:
- Dotación:
- Año de incio:
- 2014
- Año de finalización:
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
Resultados del Ensayo Clínico
[Farewell open letter to SEFH members].
Editorial Material. 10.7399/fh.2015.39.6.10128. 2015
[Translated article] Cybersecurity: a priority for pharmacy services in the age of artificial intelligence
Marin, Cayetano M. Hernandez, Monte-Boquet, Emilio, Andres, Jose Luis Poveda
Editorial Material. 10.1016/j.farma.2024.08.009. 2024
[Translated article] Good humanisation practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Andrés JLP, Solsona MDE
Article. 10.1016/j.farma.2023.10.004. 2024
[Translated article] New challenges in advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2024.05.001. 2024
[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.
Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.12.007. 2025
[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.
Fernandez, Laura Lorente; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.09.006. 2024
2019 SEFH National Survey: service portfolio, care activities, education and research in Spain's hospital pharmacy departments.
Pérez-Encinas M; (...); Calleja-Hernández MÁ
Article. 10.7399/fh.11611. 2021
A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients.
Lozano ML; (...); Vicente V
Article. 10.1016/j.bcmd.2020.102505. 2021
A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study.
Rios-Tamayo, Rafael; (...); Mateos, Maria Victoria
Article. 10.1080/16078454.2023.2178997. 2023
A multicentre ambispective observational study into the incidence and clinical management of aplastic anaemia in Spain (IMAS study)
Vallejo C; (...); Codesido ML
Article. 10.1007/s00277-023-05602-x. 2024
A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain
Zozaya, Neboa; (...); Hidalgo-Vega, Alvaro
Article. 10.33393/grhta.2022.2333. 2022
A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.
Zozaya, Neboa; (...); Verde, Luis
Article. 10.1017/S0266462322000459. 2022
A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study.
de Andrés-Nogales F; (...); Martínez-Olmos J
Article. 10.1007/s41669-020-00201-2. 2020
A MULTI-STAKEHOLDER MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD STUDY.
Casado, MA; (...); Grp MULTIDEX-EMD
Meeting Abstract. 10.1016/j.jval.2018.09.2545. 2018
A new definition and refocus of pharmaceutical care: the Barbate Document
Morillo-Verdugo R; (...); Poveda-Andrés JL
Article. 10.7399/fh.11389. 2020
A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis
Cibeira, MT; (...); Blade, J
Article. 10.1111/bjh.13500. 2015
A randomized phase II study comparing consolidation with a single dose of Y-90 ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results
Lopez-Guillermo, Armando; (...); Tomas, Jose Francisco
Article. 10.1080/10428194.2021.1971216. 2021
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
Hajek, R; (...); Ludwig, H
Article. 10.1038/leu.2016.176. 2017
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Encinas, Cristina; (...); Martinez-Lopez, Joaquin
Article. 10.1038/s41408-022-00652-2. 2022
A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia
Megías-Vericat JE; (...); Aliño SF
Article. 10.1038/tpj.2015.80. 2016
Acute hemolytic reaction by anti-Wra: Case report and review of the hemovigilance database of a tertiary care hospital.
Solves, Pilar; (...); de la Rubia, Javier
Article. 10.1016/j.transci.2021.103342. 2022
ADAMTS13 RECOVERY IN ACUTE THROMBOTIC THROMBOCYTOPENIC PURPURA AFTER CAPLACIZUMAB THERAPY. THE SPANISH REGISTRY.
Mingot-Castellano, Maria Eva; (...); Pascual Izquierdo, Cristina
Article. 10.1182/blood.2023022725. 2024
Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in classical Hodgkin's lymphoma: report on three cases and literature review
Review. 10.1177/20406207211038181. 2021
Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study.
Ballesta-López O; (...); Poveda-Andrés JL
Article. 10.1177/1078155220915953. 2020
Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice
Stadtmauer, Edward A.; (...); ZOE-SCT Study Grp Collaborators
Article. 10.1080/21645515.2021.1953346. 2021
Adoptive transfer of ex-vivo expanded SARS-CoV-2-specific Cytotoxic Lymphocytes: a viable strategy for COVID-19 immunosuppressed patients?
Guerreiro M; (...); Piñana JL
Article. 10.1111/tid.13602. 2021
Aflibercept in exudative age related macular degeneration refractory to ranibizumab.
Ruiz Ramos J; (...); Gallego-Pinazo R
Article. 10.1016/j.oftal.2015.07.018. 2015
Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B- Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study
Bar, Noffar; (...); Costa, Luciano
Meeting Abstract. 10.1182/blood-2023-180013. 2023
Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
Wong, Sandy W.; (...); Costa, Luciano J.
Meeting Abstract. 10.1182/blood-2022-159009. 2022
Allogeneic hematopoietic stem cell transplantation in patients with multiple myeloma. Impact of disease characteristics, disease status at transplant, and prior number of lines of therapy. Results of retrospective, multicentre Spanish study
De la Rubia, J; (...); Gonzalez, MS
Meeting Abstract. 2019
ALLOGENEIC TRANSPLANTATION OF HEMATOPOIETIC PROGENITORS (T-ALO) IN PATIENTS WITH MULTIPLE MYELOMA (MM). IMPACT OF BIOLOGICAL CHARACTERISTICS TO DIAGNOSIS, TPH DISEASE SITUATION AND TREATMENT LINES. SPANISH MULTICENTRIC RETROSPECTIVE STUDY
Perez, A.; (...); Solano, C.
Meeting Abstract. 2019
Analysing criteria for price and reimbursement of orphan drugs in Spain.
Badia, X; (...); Tort, M
Article. 10.7399/fh.11147. 2019
Analysis of chemical contamination by hazardous drugs with BD HD Check(R) system in a tertiary hospital
Valero García S; (...); Poveda Andrés JL
Article. 10.1177/10781552211038518. 2021
Analysis of minimal residual disease in bone marrow by NGF and in peripheral blood by mass spectrometry in newly diagnosed multiple myeloma patients enrolled in the GEM2012MENOS65 clinical trial.
Puig, Noemi; (...); Mateos, Maria-Victoria
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.8010. 2021
Analysis of Peripheral Blood and Bone Marrow Residual Disease Dynamics during Intensive Treatment and Maintenance in Patients with Multiple Myeloma Included in the GEM12MENOS65 and GEM14MAIN Clinical Trials
Puig, Noemi; (...); Victoria Mateos, Maria
Meeting Abstract. 10.1182/blood-2023-184837. 2023
ANALYSIS OF PROGRESSION-FREE SURVIVAL OF AND GLOBAL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA OLDER THAN 65 YEARS CANDIDATES FOR AUTOLOGOUS PERIPHERAL BLOOD TRANSPLANTATION NON-CANDIDATES
Cejalvo, MJ; (...); De la Rubia, J
Meeting Abstract. 2017
ANALYSIS OF RESIDUAL DISEASE IN PERIPHERAL BLOOD BY MEANS OF MASS SPECTROMETRY IN PATIENTS WITH MULTIPLE MYELOMA OF THE GEM 2012 MINUS65. COMPARISON WITH THE IMWG STANDARD RESPONSE AND RESIDUAL DISEASE CRITERIA
Puig, N.; (...); Mateos, M., V
Meeting Abstract. 2021
ANALYSIS OF THE PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN ELDERLY PATIENTS (65 YEARS OLD) WITH MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION.
Cejalvo, MJ; (...); De la Rubia J
Meeting Abstract. 2018
Antimicrobial stewardship programme implementation in a medical ward
Ruiz, J; (...); Poveda, JL
Article. 2018
Antimicrobial stewardship programme in critical care medicine: A prospective interventional study
Ruiz, J; (...); Catellanos, A
Article. 10.1016/j.medin.2017.07.002. 2018
Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).
Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ
Letter. 10.1111/jdv.19432. 2023
Assessment of the quality of sample labelling for clinical research.
Pérez-Huertas P; (...); Poveda-Andrés JL
Article. 10.7399/fh.2016.40.2.9753. 2016
Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial
Puig, Noemi; (...); Mateis, Maria-Victoria
Meeting Abstract. 10.1182/blood-2021-151557. 2021
Association of SNPs with the efficacy and safety of immunosuppressant therapy after heart transplantation
Sánchez-Lázaro I; (...); Aliño SF
Article. 10.2217/pgs.15.39. 2015
Autoimmune cytopenias after umbilical cord blood transplantation in adults with hematological malignancies: a single-center experience
Article. 10.1038/bmt.2014.107. 2014
Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis
Casanova, B; (...); Coret, F
Article. 10.1007/s10072-017-2933-6. 2017
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial
Briones J; (...); Grupo Español de Linfomas y Trasplante Autologo de Médula Ósea (GELTAMO)
Letter. 10.3324/haematol.2014.108308. 2014
Autologous stem cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study.
García-Sancho AM; (...); Caballero D
Article. 10.3324/haematol.2021.279426. 2022
Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure
Jiménez-Ubieto A; (...); Lahuerta JJ
Article. 10.1016/j.bbmt.2017.05.021. 2017
Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment
Jimenez-Ubieto, A; (...); GELTAMO Grp Espanol Linfomas Tr
Article. 10.1002/hon.2553. 2018
Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy.
Jiménez-Ubieto A; (...); GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) Cooperative Stu
Article. 10.1016/j.hemonc.2019.06.001. 2019
Autologous Stem Cell Transplantation may potentially abrogate the negative prognostic effect of early relapse after chemo or inmunochemotherapy in Follicular Lymphoma
Ubieto, AJ; (...); Lahuerta, JJ
Meeting Abstract. 2018
AUTONOMOUS TRANSPLANTATION CAN MITIGATE THE ADVERSE PROGNOSIS OF THE EARLY RELAPSE AFTER CHEMO OR IMMUNOCHEMOTHERAPY INDUCTION IN FOLLICULAR LYMPHOMA
Ubieto, AJ; (...); Lahuerta, J. J.
Meeting Abstract. 2017
Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI).
Pascual-Izquierdo C; (...); Mingot-Castellano ME
Article. 10.1002/ajh.27498. 2024
Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.
Iglesias Gómez R; (...); Poveda Andrés JL
Article. 10.1136/ejhpharm-2021-002741. 2021
Bayesian pharmacokinetic individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
Megias-Vericat, JE; (...); Bonanad, S
Meeting Abstract. 2018
Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2018.12.027. 2019
Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial
Gonzalez-Calle, Veronica; (...); Mateos, Maria-Victoria
Meeting Abstract. 10.1182/blood-2022-162584. 2022
Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-VRd Trial
Gonzalez-Calle, Veronica; (...); Mateos, Maria-Victoria
Meeting Abstract. https://doi.org/10.1182/blood-2022-162584. 2024
Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort
De la Rubia, Javier; (...); Alegre, Adrian
Meeting Abstract. 10.1182/blood-2022-158538. 2022
Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain.
de la Rubia, Javier; (...); Alegre, Adrian
Article. 10.3390/cancers15112964. 2023
Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group
Redondo, AM; (...); GEL-TAMO
Article. 10.1111/bjh.15713. 2019
Bendamustine plus rituximab in untreated chronic lymphocytic leukemia patients. The MDA-CLL-2015-02 study
De La Fuente, A; (...); Baltasar, P
Meeting Abstract. 2017
Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura
Gomez-Segui, I, Izquierdo, CP, Comos, JD
Review. 10.1080/17474086.2021.1956898. 2021
Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.
Fernandez Rivera C; (...); Hernandez D
Article. 10.1111/ctr.14550. 2022
Biosimilares: viejas polemicas con nuevos argumentos.
Poveda-Andrés JL, Bosó-Ribelles V
Editorial Material. 10.7399/fh.2015.39.3.8978. 2015
BK Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation in the Pediatric Population
Perez-Huertas, P; (...); Poveda-Andres, JL
Article. 10.1177/1043454216631952. 2017
Bloodstream Infections in Adult Patients Undergoing Cord Blood Transplantation from Unrelated Donors after Myeloablative Conditioning Regimen
Article. 10.1016/j.bbmt.2014.12.038. 2015
Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial
Rosiñol L; (...); Bladé J
Article. 10.1038/leu.2017.35. 2017
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplantation in multiple myeloma.
Rosiñol L; (...); Bladé J
Article. 10.1182/blood.2019000241. 2019
Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma
Blanes M; (...); de la Rubia J
Article. 10.3109/10428194.2014.922182. 2015
Breakthrough invasive fungal disease in high-risk hematologic malignancies in children: a single-center experience
Garcia-Robles, AA; (...); Fernandez-Navarro, JM
Meeting Abstract. 2017
BUMEL vs MEL-200 prior autologous transplant for patients with newly diagnosed multiple myeloma previously treated with bortezomib, lenalidomide and dexamethasone: final results of a phase 3 trial
Lahuerta Palacios, Juan Jose; (...); Blade, Joan
Meeting Abstract. 2022
Calidad y Legibilidad de la Hoja de Informacion al Paciente en Estudios con Analisis Farmacogenetico.
Ruiz Ramos J; (...); Poveda Andrés JL
Article. 2015
Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)
Coppo, Paul; (...); Scully, Marie
Meeting Abstract. 10.1182/blood-2023-179316. 2023
Caplacizumab Treatment in Elderly Patients with iTTP: Updated Experience from the Spanish TTP Registry
Gomez Segui, Ines; (...); De La Rubia, Javier
Meeting Abstract. 10.1182/blood-2023-180970. 2023
Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.
Balaguer-Rosello, Aitana; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2020.12.019. 2021
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma.
Garces, Juan-Jose; (...); Paiva, Bruno
Article. 10.1200/JCO.21.01365. 2022
Cis-Acting Splicing-Associated Variants Can Redefine the Molecular Signature of Genes Commonly Mutated in Acute Myeloid Leukemia
Morote-Faubel, Mireya; (...); Cervera, Jose
Meeting Abstract. 10.1182/blood-2023-177571. 2023
Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study.
Rodriguez-Pinilla SM; (...); Cordoba, Raul
Article. 10.1111/bjh.16741. 2021
Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2021.07.009. 2021
Clinical Characteristics and Transfusion Management of Patients Diagnosed of Multiple Myeloma Receiving Daratumumab: Experience of a Single Centre
Arnao, M; (...); Sanz, G
Meeting Abstract. 10.1016/j.clml.2019.09.254. 2019
Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies
Askari, Elham; (...); Garcia-Sanz, Ramon
Meeting Abstract. 10.1182/blood-2023-189581. 2023
Clinical evaluation of rituximab treatment for neuromyelitis optica
Fernández-Megía MJ; (...); Poveda-Andrés JL
Article. 10.1016/j.nrl.2014.09.001. 2015
Clinical experiences with cannabinoids in spasticity management in multiple sclerosis
Lorente Fernández L; (...); Casanova-Estruch B
Article. 10.1016/j.nrl.2013.06.014. 2014
Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial
Puig, Noemi; (...); Mateos, Maria-Victoria
Meeting Abstract. 10.1182/blood-2022-165441. 2022
Clinical pharmacy services: from cost-effectiveness analysis to a productivity indicators model
Nogueras, A; (...); Calleja, MA
Letter. 10.1136/ejhpharm-2019-001905. 2019
Clinical Significance and Transcriptional Profiling of Persistent Minimal Residual Disease (MRD) in Multiple Myeloma (MM) Patients with Standard-Risk (SR) and High-Risk (HR) Cytogenetics
Goicoechea, I; (...); Paiva, B
Meeting Abstract. 10.1182/blood-2018-99-113312. 2018
CMV REACTIVATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FROM HLA-MATCHED AND HAPLOIDENTICAL DONORS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE.
Article. 10.1016/j.jtct.2024.01.082. 2024
Collaborative model of home delivery program in haemophilia through an association of patients
Megias-Vericat, JE; (...); Bonanad, S
Meeting Abstract. 2018
Common seasonal respiratory virus infections in allogeneic stem cell transplant recipients during the SARS-COV-2 pandemic.
De La Puerta R; (...); Piñana JL
Article. 10.1038/s41409-021-01319-5. 2021
COMPARATIVE STUDY OF THE CHARACTERISTICS OF THE DIAGNOSIS AND RESPONSE TO TREATMENT IN PATIENTS AGED=60 YEARS VS. <60 YEARS WITH ACQUIRED PURPLE THROMBOTIC THROMBOCYTOPENIC. RESULTS OF THE SPANISH REGISTRATION OF PTT (REPTT)
Aracil Eva, Frances; (...); Comos Javier, De la Rubia
Meeting Abstract. 2021
Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo
Megias-Vericat, JE; (...); Poveda, JL
Meeting Abstract. 2020
COMPARISON OF THREE PANELS OF NGS APPLICATION IN ONCOHEMATOLOGY TO DISCARD SOMATIC AND/OR GERMINAL VARIANTS
Guzman-Gimenez, C.; (...); Such, E.
Meeting Abstract. 2021
Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation
Article. 10.1111/ejh.13270. 2019
COMPREHENSIVE LONG-TERM FOLLOW-UP OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A REPORT FROM A SINGLE CENTRE
Sempere, A.; (...); Jarque, I.
Meeting Abstract. 2016
CONCURRENT MUTATIONS IN ZRSR2 AND TET2 CAUSE SMD-COMPATIBLE ANOMALIES IN A MOUSE MODEL
Cristian, Garcia-Ruiz; (...); Alejandra, Sanjuan-Pla
Meeting Abstract. 2021
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano JB; (...); Soto-Ortega I
Article. 10.1016/j.farma.2023.01.003. 2023
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada
Article. 10.1016/j.farma.2023.04.002. 2023
Copper deficiency: a cause of misdiagnosis of myelodysplastic syndrome
Villalba, A; (...); Senent, L
Letter. 10.1007/s00277-018-3334-5. 2018
Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain
Ostermann, H; (...); Charbonneau, C
Article. 10.1186/2050-6511-15-52. 2014
COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA
Gironella, M.; (...); Oyaguez, I
Meeting Abstract. 2019
COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN
Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.
Meeting Abstract. 2024
Cost-effectiveness analysis of implementing an antimicrobial stewardship program in critical care units
Ruiz-Ramos, J; (...); Ramirez, P
Article. 10.1080/13696998.2017.1311903. 2017
Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.
Poveda JL; (...); Torres C
Article. 10.1080/14737167.2019.1635014. 2020
COST-EFFECTIVENESS OF CLADRIBINE TABLETS AND FINGOLIMOD IN THE TREATMENT OF REMITTING MULTIPLE SCLEROSIS WITH HIGH DISEASE ACTIVITY IN SPAIN
Trillo, JL; (...); Torres, C
Meeting Abstract. 10.1016/j.jval.2018.09.2029. 2018
Cost-effectiveness of methoxy polyethylene glycolepoetin beta versus conventional epoetin in the treatment of anaemia secondary to chronic kidney disease in clinical practice
Lorente-Fernandez, L; (...); Poveda-Andres, JL
Article. 10.1136/ejhpharm-2013-000426. 2015
COSTS OF THE MANAGEMENT OF HEMOPHILIA A WITH INHIBITORS IN SPAIN
Bonanad, S; (...); Gonzalez-Dominguez, A
Meeting Abstract. 2020
Costs of the management of hemophilia A with inhibitors in Spain
Bonanad, S; (...); Gonzalez-Dominguez, A
Article. 10.33393/grhta.2021.2234. 2021
Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia
Casado, LF; (...); Castro, A
Article. 10.1111/ejh.13007. 2018
COST-UTILITY OF IDELALISIB IN COMBINATION WITH RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Casado, LF; (...); Castro-Gomez, A
Meeting Abstract. 10.1016/j.jval.2017.08.898. 2017
CRITICAL REVIEW OF THE DOUBLE NEGATIVITY IN THE SERUM AND URINE IMMUNOFIXATION (IF) TO ESTABLISH THE CATEGORY OF COMPLETE REMISSION IN MULTIPLE MYELOMA (MM)
Anglada, LL; (...); Lahuerta, J. J.
Meeting Abstract. 2017
Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis
Megias-Vericat, JE; (...); Poveda, JL
Letter. 10.1111/hae.13733. 2019
Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products
Eduardo Megias, Juan; (...); Iorio, Alfonso
Meeting Abstract. 10.1182/blood-2019-127946. 2019
Curative Strategy (GEM- CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd
Mateos, Maria-Victoria; (...); San-Miguel, Jesus F.
Meeting Abstract. 10.1182/blood-2021-148423. 2021
Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)
Mateos, Maria-Victoria; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2022-159606. 2022
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.
Mateos, Maria-Victoria; (...); San-Miguel, Jesus F
Article. 10.1200/JCO.23.02771. 2024
Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective
Hubel, K; (...); Corradini, P
Review. 10.1111/ejh.12362. 2015
Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.
Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL
Editorial Material. 10.1016/j.farma.2024.08.001. 2024
CYTOGENETIC ANALYSIS IN REAL LIFE IN PATIENTS WITH MULTIPLE MYELOMA NEW DIAGNOSIS Results: FROM THE MULTIPLE MYELOMA STUDY GROUP OF THE VALENCIAN COMMUNITY (GREMI)
Gomez, Beltran Elena; (...); De la Rubia, Comos Javier
Meeting Abstract. 2020
Cytogenetic Assessment and Risk Stratification in Myelofibrosis with Optical Genome Mapping.
Diaz-Gonzalez, Alvaro; (...); Such, Esperanza
Article. 10.3390/cancers15113039. 2023
Cytokine response as a biomarker for early diagnosis and outcome prediction of stem cell transplant recipients and acute leukemia patients with invasive aspergillosis.
Puerta-Alcalde, Pedro; (...); Garcia-Vidal, Carolina
Article. 10.1093/mmy/myac038. 2022
Chronic liver disease-associated severe thrombocytopenia in Spain: Results from a retrospective study using machine learning and natural language processing.
Calleja-Panero, Jose Luis; (...); Gonzalez Calvo, Jose
Article. 10.1016/j.gastrohep.2023.05.010. 2023
CHRONOLOGICAL AGE AS A PROGNOSTIC FACTOR IN PATIENTS WITH MULTIPLE MYELOMA NEW DIAGNOSIS NOT CANDIDATED FOR TRANSPLANTATION
Martinez Elena, Meseguer; (...); Comos Javier, De la Rubia
Meeting Abstract. 2021
Chronological age as a prognostic factor in transplant-ineligible patients with newly diagnosed Multiple Myeloma
Garcia Ruiz, Raquel; (...); de la Rubia, Javier
Meeting Abstract. 2021
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
Moreau, Philippe; (...); Goldschmidt, Hartmut
Letter. 10.1038/s41408-023-00805-x. 2023
Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.1080/17512433.2019.1573668. 2019
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (vol 11, 16867, 2021)
Lozano, Maria L.; (...); Vicente, Vicente
Article. 10.1038/s41598-021-95732-x. 2021
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia.
Lozano ML; (...); Vicente V
Article. 10.1038/s41598-019-53209-y. 2019
DEEP INTRONIC MUTATIONS IN THE RUNX1 AND FLT3 GENES PRODUCE OPENING SPLICING IN PATIENTS WITH MYELODYSPLASIC SYNDROMES
Mireia, Boluda-Navarro; (...); Jose, Cervera
Meeting Abstract. 2021
Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project
Blade, J; (...); Lizan, L
Article. 10.1136/bmjopen-2017-018850. 2018
Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies
Burgos, Leire; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2021-150092. 2021
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.
Burgos, Leire; (...); Paiva, Bruno
Article. 10.1200/JCO.22.01916. 2023
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
Lahuerta, JJ; (...); GEM (Grupo Español de Mieloma)
Article. 10.1200/JCO.2016.69.2517. 2017
Depth of Response of Isatuximab (Isa) plus Carfilzomib (K) and Dexamethasone (d) in Relapsed Multiple Myeloma: IKEMA Updated Analysis
Joseph, Mikhael; (...); Meletios, A. Dimopoulos
Article. 2022
Depth of response of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma: IKEMA updated analysis
Hajek, Roman; (...); Dimopoulos, Meletios A.
Meeting Abstract. 2022
DESCRIPTIVE STUDY OF THE RECORD OF THROMBOTIC MICROANGIOPATHY IN A SINGLE CENTRE
Romero Dominguez, S.; (...); Sanz Alonso, M. A.
Meeting Abstract. 2015
Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.
Salinas P; (...); Escaned J
Article. 10.1016/j.carrev.2021.11.015. 2021
DETERMINATION OF THE CHALLENGES AND OPPORTUNITIES ASSOCIATED WITH PLATELET TRANSFUSION IN THE MANAGEMENT OF PATIENTS WITH SEVERE THROMBOCYTOPENIA ASSOCIATED WITH CHRONIC LIVER DISEASE
Jarque, Ramos, I; (...); Shepherd, Moreno J.
Meeting Abstract. 2020
DETERMINING THE EPIDEMIOLOGY, PATIENT FLOW, TREATMENT AND UNMET NEEDS OF PATIENTS WITH CHRONIC LIVER DISEASE-ASSOCIATED SEVERE THROMBOCYTOPENIA UNDERGOING INVASIVE PROCEDURES IN SPAIN
Andrade, R.; (...); Shepherd, J.
Meeting Abstract. 2019
Determining the value contribution of emicizumab (Hemlibra (R)) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis
Alvarez-Roman, MT; (...); Badia, X
Article. 10.1177/2284240319880534. 2019
DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)
Alvarez, E.; (...); Badia, F. J.
Meeting Abstract. 2019
Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.
Abad, Maria Reyes; (...); Gil, Alicia
Article. 10.33393/grhta.2024.3041. 2024
Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis
Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther
Article. 10.1002/jvc2.275. 2024
Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale
Bonanad S; (...); GAH Group
Article. 10.1016/j.jgo.2015.03.003. 2015
DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN
Poveda, J. L.; (...); Vitoria, I
Meeting Abstract. 2019
Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain
Badia, X; (...); Poved, JL
Article. 10.1080/21678707.2019.1652163. 2019
Dexamethasone does not prevent malignant cell reintroduction in leukemia patients undergoing ovarian transplant: risk assessment of leukemic cell transmission by a xenograft model
Diaz-Garcia, C; (...); Pellicer, A
Article. 10.1093/humrep/dez115. 2019
Diffusion tensor imaging as a prognostic biomarker for motor recovery and rehabilitation after stroke
Puig, J; (...); Pedraza, S
Review. 10.1007/s00234-017-1816-0. 2017
Disseminated toxoplasma infection after hematopoietic stem cell transplantation with myositis and encephalitis.
Asensi Cantó P; (...); Guerreiro M
Article. 10.1111/tid.14067. 2023
Do Guidelines Influence Diagnostic and Therapeutic Practice in Immune Thrombocytopenia? Results of a Multicenter Retrospective Study
Luisa Lozano, Maria; (...); Vicente Garcia, Vicente
Meeting Abstract. 10.1182/blood-2019-125557. 2019
Dose banding aplicado a la elaboracion de antineoplasicos: una revision narrativa de la literatura.
Pérez Huertas P; (...); Poveda Andrés JL
Article. 10.7399/fh.2015.39.4.8839. 2015
Drug Interaction Between Oral Cyclosporine Modified and Iron
Domingo-Chiva, E; (...); Poveda-Andres, JL
Article. 10.1177/1060028013514734. 2014
Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann-Pick type C disease: review of initial published cases
Megias-Vericat, JE; (...); Poveda, JL
Review. 10.1007/s10072-017-2833-9. 2017
Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant
Solano C; (...); Bow EJ
Article. 10.1111/myc.12552. 2017
ECONOMIC IMPACT LINKED TO THE REDUCTION OF EXACERBATIONS WHEN A TREATMENT REGIME WITH INHALED ANTIBIOTICS IS SWITCHED TO AZTREONAM LYSINE IN PATIENTS WITH CYSTIC FIBROSIS AND CHRONIC PULMONARY INFECTION CAUSED BY PSEUDOMONAS AERUGINOSA
Sole A; (...); Casado MA
Meeting Abstract. 10.1016/j.jval.2014.08.1659. 2014
Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan
Ribera, E; (...); Hernandez-Novoa, B
Article. 10.1016/j.eimc.2016.11.015. 2018
Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome
Cañigral C; (...); Sanz MA
Letter. 10.1007/s00277-013-1970-3. 2014
Editorial: Infectious diseases and hematology: diagnosis and management
Gonzalez-Lopez, Tomas Jose; (...); Di Micco, Pierpaolo
Editorial Material. 10.3389/fmed.2024.1385874. 2024
Efecto de la adición de fortificantes y de módulo de proteínas en la osmolalidad de la leche materna donada.
Torres Martínez E; (...); Vento M
Article. 10.1016/j.anpedi.2020.03.009. 2020
Effect of Caplacizumab in the Recovery of ADAMTS13 Level in Patients with Autoimmune Thrombotic Thrombocytopenic Purpura. Analysis from the Spanish Registry (REPTT)
Eva Mingot, Maria; (...); Del Rio Garma, Julio
Meeting Abstract. 10.1182/blood-2023-182876. 2023
Effect of CD8(+) Cell Content on Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies
Moscardó F; (...); Sanz GF
Article. 10.1016/j.bbmt.2014.06.038. 2014
Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies
Rojas L; (...); Aliño SF
Article. 10.1038/tpj.2014.38. 2015
EFFECT OF PREGNANCY IN THE CLINICAL COURSE OF PREGNANT WOMEN WITH PTI AND THEIR OFFSPRING. RESULTS OF A SERIES OF SPANISH CASES WITH 263 PREGNANCIES IN PRIMARY PTI
Lopez, TJG; (...); Hermida, G.
Meeting Abstract. 2017
Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial
Bastidas, A; (...); ZOE-HSCT Study Grp Collaborators
Article. 10.1001/jama.2019.9053. 2019
Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment
Palanques-Pastor T; (...); Poveda Andrés JL
Article. 10.1159/000517813. 2021
eLearning of pharmacokinetic monitoring in hemophilia with application in the clinical practice
Bonanad, S; (...); Megias-Vericat, JE
Meeting Abstract. 2018
Elotuzumab plus bortezomib and dexamethasone (EBd) versus bortezomib and dexamethasone (Bd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM)-2-year follow-up
Palumbo, A; (...); Jakubowiak, A
Article. 2016
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
Peffault de Latour R; (...); Risitano AM
Article. 10.1056/NEJMoa2109965. 2022
ELTROMBOPAG ADDED TO STANDARD IMMUNOSUPPRESSION IMPROVES RESPONSE RATE IN SEVERE APLASTIC ANEMIA: RESULTS OF THE MULTICENTER PHASE III PROSPECTIVE RANDOMIZED RACE TRIAL
Risitano, A. M.; (...); de latour, R. Peffault
Meeting Abstract. 2021
ELTROMBOPAG ADDED TO STANDARD IST IS SUPERIOR TO IST ALONE AS FRONT-LINE TREATMENT FOR SEVERE APLASTIC ANEMIA: FINAL 2-YEAR ANALYSIS OF EBMT-SAAWP RACE STUDY
Risitano, Antonio Maria; (...); de Latour, Regis Peffault
Meeting Abstract. 2024
Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice
González-López TJ; (...); González-Porras JR
Article. 10.1111/ejh.12725. 2016
Enhancing Cytogenetic Diagnostics: Incorporating Optical Genome Mapping in the Laboratory Routine
Diaz-Gonzalez, Alvaro; (...); Such, Esperanza
Meeting Abstract. 10.1182/blood-2023-180691. 2023
Epidemiology of Hereditary Thrombotic Thrombocytopenic Purpura (TTP) in Spain: Preliminary Results of a Study of the Spanish TTP Registry (REPTT)
Segui, Ines Gomez; (...); Garma, Julio Del Rio
Meeting Abstract. 2024
Estimating the Patient-Specific Relative Stiffness Between a Hepatic Lesion and the Liver Parenchyma
Martinez-Sanchis, S; (...); Lopez-Andujar, R
Proceedings Paper. 10.1007/978-3-319-68195-5_53. 2018
Estimating the Relative Stiffness between a Hepatic Lesion and the Liver Parenchyma through Biomechanical Simulations of the Breathing Process
Martinez-Sanchis, S; (...); Monserrat, C
Article. 10.1155/2018/5317324. 2018
European Perspective on Multiple Myeloma Treatment Strategies in 2014
Ludwig H; (...); Palumbo A
Article. 10.1634/theoncologist.2014-0042. 2014
EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING & REIMBURSEMENT (P&R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN
Badia, F. J.; (...); Shepherd, J.
Meeting Abstract. 2019
Evaluation of minimal residual disease in relapsed/refractory multiple myeloma patients treated with venetoclax or placebo in combination with bortezomib and dexamethasone: BELLINI study analyses.
Moreau, P; (...); Kumar, S
Meeting Abstract. 2020
Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with hematological malignancies.
Gudiol C; (...); de la Cámara R
Article. 10.1016/j.eimc.2019.01.013. 2020
Experience in the management of immunosuppressant treatment with hepatitis C virus protease inhibitors
Ruiz Ramos J; (...); Poveda Andrés JL
Article. 10.1016/j.gastrohep.2014.05.004. 2014
Experience of Home Delivery Program in Haemophilia Through an Association of Patients
Megias Vericat, J. E.; (...); Bonanad Boix, S.
Meeting Abstract. 2017
EXPERTS CONSENSUS ON THE FUTURE OF RARE DISEASES CARE AND ORPHAN DRUGS ACCESS IN SPAIN: A DELPHI STUDY
Paz S; (...); Urcelay J
Meeting Abstract. 10.1016/j.jval.2015.09.2016. 2015
Exploratory analysis for the implementation of antineoplastic logarithmic dose banding
Albert-Mari, A; (...); Poveda-Andres, JL
Article. 10.1007/s11096-018-0714-9. 2018
EXTENDED MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD EXTENSION STUDY
F, de Andres-Nogales; (...); Martinez, M.
Meeting Abstract. 2019
Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease
Beltran, B; (...); Nos, P
Article. 10.1159/000492626. 2019
Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report
Fernandez-Sanchez, M; (...); Poveda-Andres, JL
Article. 10.1002/bdr2.1942. 2021
FINAL ANALYSIS OF GLOBAL SURVIVAL OF THE FIRST TEST IN PATIENTS WITH MULTIPLE NEW DIAGNOSTIC MYELOMA
Oriol, A.; (...); Benboubker, L.
Meeting Abstract. 2017
Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Ayyappan, Sabarish; (...); Prince, H. Miles
Meeting Abstract. 10.1182/blood-2023-179818. 2023
Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice.
Gonzalez-Lopez, Tomas Jose; (...); Garcia-Donas Gabaldon, Gloria
Article. 10.1182/blood.2024024250. 2024
Frequency, characteristics and outcomes of Lymphoproliferative Disorders After Allogeneic Stem Cell Transplant: results of a multicenter study from the Grupo Espanol de Trasplante Hematopoyetico (GETH)
Garcia Cadenas, Irene; (...); Solano, Carlos
Meeting Abstract. 2018
Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH)
Garcia-Cadenas, I; (...); Spanish Grp Blood & Marrow Tran
Article. 10.1111/ejh.13226. 2019
Further psychometric validation of the GAH scale: Responsiveness and effect size
Cruz-Jentoft, AJ; (...); GAH Group
Article. 10.1016/j.jgo.2016.12.008. 2017
GAH SCALE PREDICTS TREATMENT TOLERABILITY IN OLDER PATIENTS (> 65 YEARS) DIAGNOSED WITH HEMATOLOGICAL MALIGNANCIES
Bonanad, S; (...); de la Rubia, J
Meeting Abstract. 2017
Gastric Bleeding in Stem Cell Transplantation: A Focus on Gastric Vascular Ectasia Under Post-Transplant Cyclophosphamide, Sirolimus, and Mycophenolate Mofetil Prophylaxis.
Eirís J; (...); Sanz J
Article. 10.1016/j.jtct.2024.10.009. 2024
Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.
Plaza J; (...); Moret-Tatay I
Article. 10.3390/ijms25073717. 2024
Genomic profiling of high-risk smoldering myeloma patients treated with a curative strategy: a biological study of the phase II GEM CESAR clinical trial
Medina, Alejandro; (...); Garcia-Sanz, Ramon
Meeting Abstract. 2023
Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study.
de la Rubia J; (...); Bonanad, Santiago
Article. 10.1016/j.jgo.2022.10.016. 2022
GERMINAL PREDISPOSITION IN PATIENTS WITH MYELOID NEOPLASMS: ASSOCIATION BETWEEN MOLECULAR DISORDERS AND CLINICAL HISTORY
Marta, Santiago; (...); Jose, Cervera
Meeting Abstract. 2021
GERMLINE PREDISPOSITION TO MYELOID MALIGNANCIES IN A CONSECUTIVE COHORT OF 183 PATIENTS
Santiago, M.; (...); Cervera-Zamora, J.
Meeting Abstract. 10.1016/j.leukres.2023.107247. 2023
Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis
Editorial Material. 2022
GUIDELINES OF PRESCRIPTION IN FIRST LINE OF PATIENTS WITH MULTIPLE MYELOMA NOT CANDIDATES TO TRANSPLANTATION STRATIFIED BY AGE IN REAL LIFE IN SPAIN BETWEEN 2012 AND 2016
Cejalvo, M. J.; (...); Sarra, J.
Meeting Abstract. 2019
Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report
Company-Albir, MJ; (...); Poveda, JL
Article. 10.1111/jcpt.12568. 2017
Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC)
López Rubio M; (...); Garcia-Marco JA
Article. 10.3109/10428194.2013.827187. 2014
Hazardous drugs levels in compounding area surfaces of Hospital Pharmacies Services: multicentric study
Valero-Garcia, S; (...); Spanish Hosp Pharmacy Units
Article. 10.7399/fh.10935. 2018
Hazardous drugs: new challenges, new opportunities.
Valero García S; (...); Poveda Andrés JL
Article. 10.7399/fh.2016.40.2.10462. 2016
Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
Solana-Altabella, Antonio; (...); Martinez-Cuadron, David
Article. 10.3390/cancers14081921. 2022
Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study
Iskierka-Jazdzewska, Elzbieta; (...); Ivanescu, Cristina
Meeting Abstract. 10.1182/blood-2023-180743. 2023
High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.
El-Qutob D; (...); Carrera-Hueso FJ
Article. 10.1016/j.hrtlng.2022.02.003. 2022
High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance
Garcia-Marco, JA; (...); GELLC Study Grp
Article. 10.3324/haematol.2018.204891. 2019
High-permeability region size on perfusion CT predicts hemorrhagic transformation after intravenous thrombolysis in stroke
Puig, J; (...); Castellanos, M
Article. 10.1371/journal.pone.0188238. 2017
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience
Rodriguez-Otero, Paula; (...); Gutierrez, Norma
Meeting Abstract. 2023
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience
Gonzalez-Calle, Veronica; (...); Gutierrez, Norma C.
Article. 10.1002/hem3.70031. 2024
High-risk gastrointestinal stromal tumour (GIST) and synovial sarcoma display similar angiogenic profiles: a nude mice xenograft study
Giner, Francisco; (...); Llombart-Bosch, Antonio
Article. 10.3332/ecancer.2017.726. 2017
Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies
Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo
Article. 10.7399/fh.11729. 2022
Hospitalization budget impact during the COVID-19 pandemic in Spain.
Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.
Article. 10.1186/s13561-021-00340-0. 2021
How can artificial intelligence optimize value-based contracting?
Poveda, Jose Luis; (...); Medrano, Ignacio H.
Letter. 10.1186/s40545-022-00475-3. 2022
How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
de Arriba de la Fuente, Felipe, Montes Gaisan, Carmen, de la Rubia Comos, Javier
Review. 10.3390/cancers15010155. 2023
Identification Of Actionable Genetic Targets In Primary Cardiac Sarcomas
Salvador-Coloma, C; (...); de Mora, JF
Article. 10.2147/OTT.S214319. 2019
IDIOPATHIC UPPER GASTROINTESTINAL BLEEDING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: AN UNPRECEDENTED COMPLICATION
Eiris, Juan; (...); Balaguer-Rosello, Aitana
Meeting Abstract. 2024
IFISTRATEGY: Spanish National Survey of Invasive Fungal Infection in Hemato-Oncologic Patients.
Vallejo, Carlos; (...); Peman, Javier
Article. 10.3390/jof9060628. 2023
Immune biomarkers of survival and infection-related mortality in multiple myeloma (MM) patients treated with lenalidomide and dexamethasone (Rd)
Maia, Catarina; (...); Paiva, Bruno
Meeting Abstract. 2022
Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)
Maia, Catarina; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2022-163058. 2022
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis
Paiva B; (...); Spanish Myeloma Group
Article. 10.1182/blood-2015-10-662320. 2016
IMMUNE THROMBOCYTOPENIA AND PREGNANCY: A SPANISH CASE SERIES OF 270 PREGNANCIES IN PRIMARY ITP.
Gonzalez-Lopez, TJ; (...); Porras, JRG
Meeting Abstract. 2017
Immune thrombotic thrombocytopenic purpura in older patients: Results from the Spanish TTP Registry (REPTT).
Gomez-Segui, I; (...); de la Rubia Comos, J
Article. 10.1111/bjh.19109. 2023
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
Perez, C; (...); Programa Estudio Terapeutica Hemop
Article. 10.1182/blood.2019004537. 2020
Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease.
Lakhwani S; (...); Hernández MT
Article. 10.1007/s00277-024-06031-0. 2024
Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease
Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro
Meeting Abstract. 10.1182/blood-2022-166826. 2022
Immunoreactivity using anti-ERG monoclonal antibodies in sarcomas is influenced by clone selection
Machado, I; (...); Llombart-Bosch, A
Article. 10.1016/j.prp.2014.04.005. 2014
Immunotherapy in multiple myeloma.
Asensi Cantó P, Arnao Herraiz M, de la Rubia Comos J
Article. 10.1016/j.medcli.2023.11.019. 2024
Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1080/10428194.2016.1231405. 2017
Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart (R) in patients with multiple sclerosis
Edo Solsona MD; (...); Poveda Andrés JL
Article. 10.2147/PPA.S127508. 2017
IMPACT OF ADHERENCE ON SUBCUTANEOUS INTERFERON BETA-1A EFFECTIVENESS ADMINISTERED BY REBISMART (R) IN PATIENTS WITH MULTIPLE SCLEROSIS
Edo-Solsona, M.; (...); Poveda-Andres, J.
Meeting Abstract. 10.1016/j.jval.2016.09.512. 2016
Impact of an antimicrobial stewardship program on critical haematological patients.
Ruiz-Ramos, J; (...); Ramirez, P
Article. 10.7399/fh.2017.41.4.10709. 2017
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1080/10428194.2020.1839650. 2020
Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1038/tpj.2017.19. 2018
Impact of natural-killer immune reconstitution on the development of cytomegalovirus infection, non-relapse mortality, and graft versus host disease after allogeneic stem cell transplantation
Rodriguez-Veiga, R.; (...); Sanz, M. A.
Meeting Abstract. 2015
Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1097/FPC.0000000000000286. 2017
IMPACT OF POSTTRANSPLANT CYCLOPHOSPHAMIDE ON TRANSFUSION REQUIREMENTS IN HLA MATCHED SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.
Marco-Ayala, Javier; (...); Solves, Pilar
Article. 10.1016/j.jtct.2023.01.009. 2023
Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation
Ruiz J; (...); Aliño SF
Article. 10.3390/ijms160920168. 2015
Impact of t(11;14) according to induction regimen in newly diagnosed transplant-eligible multiple myeloma patients: long term follow-up of GEM05MENOS65 and GEM2012 PETHEMA/GEM studies
Moreno, David; (...); Rosinol, Laura
Meeting Abstract. 2021
Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019
Badia X; (...); Hernández C
Article. 10.1186/s13023-020-01507-4. 2020
Impact of Transporter Genes Polymorphisms in Standard Induction of Acute Myeloid Leukemia
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Meeting Abstract. 2015
Impact of voriconazole plasma concentrations on treatment response in critically ill patients
Ruiz, J; (...); Ramirez, P
Article. 10.1111/jcpt.12817. 2019
Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases
Edo-Solsona, MD, Vitoria-Minana, I, Poveda-Andres, JL
Article. 10.7399/fh.11262. 2020
Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients
Ruiz-Ramos, J; (...); Ramirez, P
Article. 10.1159/000478969. 2018
Improved outcomes in allo-HCT for multiple myeloma patients with thiotepa-busulfan-fludarabine conditioning regimen and post-transplant cyclophosphamide, sirolimus and mycophenolate mofetil
de la Rubia, Javier; (...); Sanz, Miguel
Meeting Abstract. 2023
INCIDENCE AND CHARACTERISTICS OF BACTERIAL INFECTIONS DURING THE THERAPY OF INDUCTION IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH NEW DRUGS. STUDY OF 67 PATIENTS FROM A SINGLE CENTRE
Martinez Garcia, M. F.; (...); Sanz Alonso, M. A.
Meeting Abstract. 2015
INCIDENCE AND CHARACTERISTICS OF POST-TRANSPLANT ALLOGENIC LYMPHOPROLIFERATIVE SYNDROMES. EXPERIENCE OF SPANISH GROUP OF HEMATOPOIETIC TRANSPLANT (GETH)
San Segundo, LY; (...); Solano, C.
Meeting Abstract. 2017
Incidence and Management of Aplastic Anemia in Spain (IMAS). An Ambispective Study of Biodonostia / Pethema
Vallejo, C; (...); Jarque, I
Meeting Abstract. 2020
Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.
Rodríguez-Veiga R; (...); Sanz GF
Article. 10.1007/s00277-019-03744-5. 2019
Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia
Boluda, Blanca; (...); Montesinos, Pau
Article. 10.3390/cancers15082267. 2023
Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis
Montesinos P; (...); Sanz MA
Article. 10.1038/bmt.2015.181. 2015
Incidence, Diagnosis, and Outcome of Acquired Thrombotic Thrombocytopenic Purpura (aTTP): A Nationwide Survey By the Spanish Apheresis Group
Izquierdo, Maria Cristina Pascual; (...); Salinas, Ramon
Meeting Abstract. 10.1182/blood-2019-123258. 2019
Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura
Pascual-Izquierdo, C; (...); Salinas, R
Article. 10.1002/jca.21894. 2021
Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide.
Asensi Cantó P; (...); Sanz J
Article. 10.1038/s41409-024-02391-3. 2024
Incidence, risk factors, and outcomes of BK hemorrhagic cystitis in hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplant cyclophosphamide.
Chorao, Pedro; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2024.12.006. 2024
Incompatibility of undiluted busulfan injection with a needle-free valve
Cueto-Sola, M; (...); Poveda-Andres, JL
Letter. 10.2146/ajhp140111. 2014
INCORPORATION OF DARATUMUMAB IN COMBINATION TO THE THERAPEUTIC PANORAMA OF PATIENTS WITH MULTIPLE MYELOMA IN RECAIDA: RESULTS OF HABITUAL CLINICAL PRACTICE IN SPAIN. GEMINI STUDY
Rios-Tamayo, R.; (...); Mateos Manteca, M., V
Meeting Abstract. 2019
Individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
Vericat, JEM; (...); Bonanad, S
Meeting Abstract. 2018
Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables
Megias-Vericat, Juan Eduardo; (...); Bonanad, Santiago
Meeting Abstract. 10.1182/blood.V128.22.3802.3802. 2016
Infections of the Central Nervous System after Untelated Donor Umbilical Cord Blood Transplantation or Human teukocyte Antigen-Matched Sibling Transplantation
Balaguer Rosello A; (...); Sanz, J
Article. 10.1016/j.bbmt.2016.10.005. 2017
Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: A systematic review and meta-analysis of observational studies
Megías-Vericat JE; (...); Aliño SF
Review. 10.1038/tpj.2014.80. 2015
Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study
Luisa Lozano, Maria; (...); Vicente Garcia, Vicente
Meeting Abstract. 10.1182/blood-2019-122237. 2019
Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy
Bastida, G; (...); Nos, P
Meeting Abstract. 10.1093/ecco-jcc/jjy222.581. 2019
Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment
Megias-Vericat, JE; (...); Aliño SF
Article. 10.1080/10428194.2017.1323267. 2017
Influence of pharmacokinetic/pharmacodynamic ratio on vancomycin treatment response in paediatric patients with Staphylococcus aureus bacteremia.
Ruiz J; (...); Poveda JL
Article. 10.23736/S0026-4946.18.04978-2. 2018
Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1097/FPC.0000000000000431. 2021
Influence of Single Nucleotide Polymorphisms in Anthracycline Metabolism Pathway in Standard Induction of Acute Myeloid Leukemia
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Meeting Abstract. 2015
Interdisciplinary recommendations document to improve adherence in patients with chronic inflammatory diseases: Adhing recommendations.
Bermejo San José F; (...); Sanromán-Álvarez L
Article. 10.7399/fh.2016.40.5.10180. 2016
Intimal Sarcoma with MDM2/CDK4 Amplification and p16 Overexpression: A Review of Histological Features in Primary Tumor and Xenograft, with Immunophenotype and Molecular Profiling.
Giner, Francisco; (...); Llombart-Bosch, Antonio
Article. 10.3390/ijms24087535. 2023
Intraperitoneal vancomycin in neonates during peritoneal dialysis: A case report
Company-Albir, MJ; (...); Poveda, JL
Article. 10.1111/jcpt.12842. 2019
Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma
Blanes, M; (...); de la Rubia, J
Letter. 10.1007/s00277-019-03663-5. 2019
Intravenous Busulfan-Melphalan vs Melphalan as Preparative Regimen for Newly Diagnosed Multiple Myeloma: Long-Term Follow-Up of a Case-Control Study
Blanes, M; (...); de la Rubia, J
Meeting Abstract. 10.1016/j.clml.2019.09.473. 2019
Intravenous busulphan plus melphalan versus melphalan alone as conditioning regimen for newly diagnosed patients with multiple myeloma: Long-term follow-up of a matched case-controlled study
Blanes, M; (...); de la Rubia, J
Meeting Abstract. 2019
Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol.
Solana-Altabella A; (...); Poveda JL
Article. 10.1177/1078155220904410. 2020
Invasive mould disease in haematological patients
Ruiz-Camps, I, Jarque, I
Review. 10.1016/j.riam.2014.06.002. 2014
Invasive yeast infections in neutropenic patients
Camps, IR, Jarque, I
Review. 10.1016/j.riam.2015.11.001. 2016
Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19
Palanques-Pastor, T, Lopez-Briz, E, Andres, JLP
Article. 10.1136/ejhpharm-2020-002322. 2020
Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.
Pozo-Rosich P; (...); Irimia P
Article. 10.1186/s10194-024-01747-w. 2024
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma according to prior lines of treatment and refractory status: IKEMA subgroup analysis.
Hajek, Roman; (...); Dimopoulos, Meletios A.
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.8034. 2021
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.
Dimopoulos, Meletios A.; (...); Hajek, Roman
Article. 10.1002/ajh.26602. 2022
Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.
Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula
Article. 10.3390/antibiotics13080706. 2024
Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial
Puig, Noemi; (...); Victoria Mateos, Maria
Meeting Abstract. 10.1182/blood-2023-182964. 2023
ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results
Ghobrial, Irene; (...); Mateos, Maria-Victoria
Meeting Abstract. 2021
Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial
Rosinol, Laura; (...); Blade Creixenti, Joan
Meeting Abstract. 10.1182/blood-2021-146798. 2021
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker L; (...); FIRST Trial Team
Article. 10.1056/NEJMoa1402551. 2014
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.
Rosinol, Laura; (...); Blade, Joan
Article. 10.1182/blood.2022019531. 2023
LENALIDOMIDE IN COMBINATION WITH R-ESHAP IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMAS (DLBCL) REFRACTORY OR IN RELAPSE: STUDY PHASE 2 OF THE GELTAMO SPANISH GROUP
Baile, M.; (...); Martin, A. A.
Meeting Abstract. 2017
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO.
Martin Garcia-Sancho, A.; (...); Caballero, D.
Article. 10.1111/bjh.18989. 2023
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial
Mateos, MV; (...); Miguel, JFS
Article. 10.1016/S1470-2045(16)30124-3. 2016
Long Term Discontinuation of Eltrombopag after Remission in Primary Immune Thrombocytopenia: 8-Year Follow-up Data from 15 Spanish Centers
Jose Gonzalez-Lopez, Tomas; (...); Sanz, Miguel A.
Meeting Abstract. 10.1182/blood-2019-129274. 2019
Longitudinal outcome over four decades of allogeneic stem cell transplantation: a single center experience.
Sanz, Miguel Angel; (...); Sanz, Jaime
Article. 10.1038/s41409-024-02319-x. 2024
Management of Adult Patients with Primary Immune Thrombocytopenia (ITP) in Clinical Practice: A Consensus Approach of the Spanish ITP Expert Group.
Mingot-Castellano ME; (...); González Porras JR
Article. 10.1155/2019/4621416. 2019
Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts
Calleja-Panero, JL; (...); Gil, A
Article. 10.17235/reed.2020.6895/2020. 2020
Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.
Megías-Vericat JE; (...); Poveda-Andrés JL
Article. 2021
Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.
Vázquez Polo A; (...); Vázquez Costa JF
Article. 10.20960/nh.03946. 2022
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.
Puig, Noemi; (...); Mateos, Maria-Victoria
Article. 10.1182/bloodadvances.2021006762. 2022
Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A
Bonanad, S; (...); Santos, S
Article. 10.1007/s12325-021-01853-0. 2021
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
Paiva B; (...); GEM (Grupo Español de Mieloma)
Article. 10.1200/JCO.19.01231. 2020
Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Article. 10.3390/cancers14030596. 2022
Metyrapone as treatment in the neonatal McCune-Albright syndrome
de Mingo, Carmen; (...); Garcia-Robles, Ana
Article. 10.1515/jpem-2020-0036. 2020
MODELING OF IDH2 GENE MUTATIONS IN THE CAENORHABDITIS ELEGANS ORGANISM. DEVELOPMENT OF A NEW STUDY MODEL
Gonzalez-Romero, E.; (...); Cervera-Zamora, J.
Meeting Abstract. 2021
MOLECULAR APPROACH TO CHRONIC LYMPHOPROLIFERATIVE SYNDROMES IN THE DAILY CLINICAL PRACTICE OF A SINGLE CENTER
Mariam, Ibanez; (...); Irene, Luna
Meeting Abstract. 2021
MOLECULAR CHARACTERIZATION OF MULTIPLE MYELOMA PATIENTS BY USING A SINGLE ENRICHMENT PANEL IDENTIFYING SNVS, INDELS, CNVS AND TRANSLOCATIONS
Juan Manuel, Rosa-Rosa; (...); Joaquin, Martinez-Lopez
Meeting Abstract. 2021
Monitoring coagulation factors during surgery. A systematic review
Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose
Review. 10.7399/fh.11766. 2021
Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).
Valero-García S; (...); Delgado-Sánchez O
Article. 10.7399/fh.11655. 2021
Monitoring the quality of the hospital pharmacoterapeutic process by sentinel patient program.
Fernandez-Megia, MJ; (...); Poveda Andrés JL
Article. 10.7399/fh.10793. 2018
Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments
Gomez-Cebrian, N; (...); Pineda-Lucena, A
Review. 10.3390/cancers13184544. 2021
N. VICTOR JIMENEZ TORRES (1942-2015) IN MEMORIAM
Climente Martí M, Poveda Andrés JL, Culebras J
Biographical-Item. 10.3305/nh.2015.32.4.9704. 2015
National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)
Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel
Correction. 10.7399/fh.11740. 2021
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
NEUROLOGIC COMPLICATIONS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CALCINEURIN-FREE GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS
Balaguer Rosello, Aitana; (...); Sanz, Jaime
Meeting Abstract. 2023
New challenges of advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2023.11.008. 2024
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial.
Rosa-Rosa, Juan Manuel; (...); Martinez-Lopez, Joaquin
Article. 10.3390/cancers14205169. 2022
Non-traumatic spontaneous abdominal haemorrhage
Ballesta, M.; (...); Lerga, P. Estelles
Article. 10.1016/j.rx.2022.11.003. 2023
Non-traumatic spontaneous abdominal haemorrhage.
Ballesta M; (...); Estellés Lerga P
Article. 10.1016/j.rxeng.2022.11.004. 2023
Novel EVI5::BRAF Gene Fusion in Infantile Fibrosarcoma: A Case Report and Review of Literature
Gonzalez-Lopez, Judith; (...); Giner, Francisco
Article. 10.3390/ijms26031182. 2025
Observational study to describe the impact of treatment combinations with Daratumumab versus other alternative regimens in patients with relapsed / refractory multiple myeloma. Spain real world evidence (RWE) data. GeminiS study
Tamayo, RR; (...); Mateos, MV
Meeting Abstract. 10.1016/j.clml.2019.09.245. 2019
Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis
Article. 10.1097/MD.0000000000032208. 2022
Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
Kim, Won-Seog; (...); Walewski, Jan
Meeting Abstract. 10.1182/blood-2022-158406. 2022
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.
Poveda JL; (...); Badia X
Article. 10.1186/s13023-022-02610-4. 2023
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial
Cabrero M; (...); Caballero D
Article. 10.1038/s41409-023-02171-5. 2024
Ofatumumab as Part of Reduced Intensity Conditioning in High Risk b-cell Lymphoma Patients: Results from a Prospective Multicenter Phase-II Trial
Cabrero, M; (...); Caballero, D
Meeting Abstract. 2020
Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Review. 10.3390/biology12091159. 2023
Online course of pharmacokinetic monitoring in hemophilia with application in the clinical practice
Bonanad, S; (...); Poveda, JL
Meeting Abstract. 2018
OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT
Flores-Moreno, S.; (...); Gil, A.
Meeting Abstract. 2024
P-137: ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results (vol 21, pg S109, 2021)
Ghobrial, Irene M.; (...); Mateos, Maria-Victoria
Correction. 10.1016/j.clml.2022.03.011. 2022
Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients
Ibanez, Mariam; (...); Luna I
Article. 10.3390/diagnostics12040953. 2022
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
San-Miguel, JF; (...); Richardson, PG
Article. 10.1016/S1470-2045(14)70440-1. 2014
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol
Garcia-Robles, Ana; (...); Carrascosa, MA
Article. 10.3389/fped.2020.00372. 2020
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Correction. 10.3389/fped.2021.834454. 2022
Paradoxical Findings in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors: Suboptimal Disease Control Perceived As Satisfactory
Gaya, Anna; (...); Vallejo, Carlos
Meeting Abstract. 10.1182/blood-2023-185939. 2023
Parasitic Infections in Hematopoietic Stem Cell Transplantation.
Article. 10.4084/MJHID.2016.035. 2016
Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia.
Sanz J; (...); Piñana JL
Article. 10.1016/j.bbmt.2019.08.020. 2020
Pathology reporting of bone marrow biopsy in myelofibrosis; application of the Delphi consensus process to the development of a standardised diagnostic report
Raya, JM; (...); Rozman, M
Article. 10.1136/jclinpath-2014-202246. 2014
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project
Morillo-Verdugo, R; (...); Diaz-Olmo, J
Article. 10.7399/fh.11719. 2021
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.
Morillo-Verdugo R; (...); Díaz-Olmo J
Article. 2021
Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy
Margusino-Framiñán L; (...); Morillo-Verdugo R
Article. 10.7399/fh.11498. 2020
PHARMACOECONOMIC ANALYSIS OF THE USE OF VORICONAZOLE, POSACONAZOLE AND MICAFUNGIN IN THE PRIMARY PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTS IN SPAIN
Grau S; (...); Rubio-Terrés C
Meeting Abstract. 10.1016/j.jval.2015.09.1944. 2015
Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.
Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis
Article. 10.3390/ijms26041760. 2025
Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.2174/1389200218666171101124931. 2018
Pharmacogenomics and the treatment of acute myeloid leukemia
Megías-Vericat JE; (...); Aliño SF
Review. 10.2217/pgs-2016-0055. 2016
Pharmacometabolomics by NMR in Oncology: A Systematic Review.
Gómez-Cebrián N; (...); Pineda-Lucena A
Article. 10.3390/ph14101015. 2021
Pharmacotherapeutic management of advanced therapy medicinal products
Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia
Article. 10.7399/fh.13036. 2022
Pharmacotherapy follow-up of patients under treatment with biologic agents for chronic inflammatory systemic conditions: an agreement among hospital pharmacists for the standardized collection of a minimum set of data.
Calleja Hernández MÁ; (...); Aragon, B
Article. 10.7399/fh.2017.41.1.10463. 2017
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia
Robak, T; (...); Jolles, S
Article. 10.1182/bloodadvances.2020002003. 2020
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial
Cabrero, M; (...); Caballero, D
Article. 10.1016/j.bbmt.2016.10.003. 2017
Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation
Vallejo C; (...); Jarque I
Article. 10.3324/haematol.2014.105908. 2014
Physical Activity In Haemophilia: Hemorrhagic Risk And Factor Levels (myPKFiT)
Querol-Fuentes, F; (...); Bonanad, S
Meeting Abstract. 2017
Pilot evaluation of home delivery programme in haemophilia
Megias-Vericat, JE; (...); Poveda-Andres, JL
Article. 10.1111/jcpt.12718. 2018
PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS
Vericat, JEM; (...); Iorio, A
Meeting Abstract. 2020
Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis
Megías-Vericat JE; (...); Aliño SF
Letter. 10.1038/tpj.2015.79. 2016
Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia.
Lazzari, Lorenzo; (...); Sanz, Jaime
Article. 10.1038/s41409-022-01725-3. 2022
Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.
Article. 10.1080/10428194.2018.1474462. 2019
Practical guide to emergency treatment of thrombotic microangiopathy
Romero S; (...); Grupo de Microangiopatía Trombótica del Hospital Universitario y Politécnico La
Editorial Material. 10.1016/j.medcli.2018.01.013. 2018
Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process
Valero, S; (...); Poveda, JL
Article. 10.1016/j.yrtph.2018.03.001. 2018
Predictive Factors for Thrombopoietin Receptor Agonist Free Responses in Chronic ITP Patients: A Multicenter Retrospective Study with Long-Term Follow-up
Luisa Lozano, Maria; (...); Vicente Garcia, Vicente
Meeting Abstract. 10.1182/blood-2019-125580. 2019
Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment
Minguela, Alfredo; (...); Periago, Adela
Article. 2021
Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment.
Minguela, Alfredo; (...); Periago, Adela
Article. 2021
PREDICTORS OF TREATMENT FREE RESPONSES WITH THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH PTI
Lozano Almela, M. L.; (...); Vicente, V.
Meeting Abstract. 2019
PRELIMINAR STUDY OF THERAPY ADHERENCE CONTROLLED BY PRESCRIPTION OF MEDICATION AND SELF-PERCEPTION ADHERENCE OF INFLAMMATORY CHRONIC DISEASE PATIENTS
Garcia, EG; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2019-eular.5937. 2019
Preparación y administración de perfusiones de insulina en neonatología: Encuesta nacional.
García-Robles A; (...); Aguar-Carrascosa M
Letter. 10.1016/j.anpedi.2020.06.008. 2021
Preparation and administration of insulin infusions in neonatology: A national survey.
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Article. 10.1016/j.anpede.2020.06.015. 2021
Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH Registry
Villegas, A; (...); Urbano, A
Article. 10.1007/s00277-017-3059-x. 2017
Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Poveda Andrés JL, Edo Solsona MD
Article. 10.1016/j.farma.2023.06.0131130. 2024
Primary and secondary immune thrombocytopenia (ITP): Time for a rethink.
Gonzalez-Lopez, Tomas Jose; (...); Fernandez-Fuertes, Fernando
Article. 10.1016/j.blre.2023.101112. 2023
Primary Central Nervous System Posttransplant Lymphoproliferative Disease in a Bilateral Transfemoral Lower Extremity Transplantation Recipient
Cavadas, PC; (...); Mayordomo-Aranda, E
Article. 10.1111/ajt.13313. 2015
Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review
Ballesta-Lopez, Octavio; (...); Luis Poveda-Andres, Jose
Review. 10.7399/fh.11780. 2021
Prognostic Impact of Anthracycline Metabolism Gene Polymorphisms in Newly Diagnosed Acute Myeloid Leukemia Adults
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Article. 2014
Prognostic Impact of Cytarabine Pathway Gene Polymorphisms in Acute Myeloid Leukemia Adults Undergoing Induction Chemotherapy
Eduardo Megias, Juan; (...); Angel Sanz, Miguel
Article. 2014
PROGNOSTIC IMPACT OF TRANSPORTER GENE POLYMORPHISMS IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA ADULTS
Megias Vericat, J. E.; (...); Sanz, M. A.
Article. 2015
Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials
Arana P; (...); San Miguel JF
Article. 10.1038/leu.2017.320. 2018
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.
Tamariz-Amador, Luis-Esteban; (...); Troconiz, Inaki F.
Article. 10.1016/j.clml.2022.04.024. 2022
Progression-free survival at 2years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma
Jimenez-Ubieto, A; (...); GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) cooperative stu
Article. 10.1002/cam4.1217. 2017
PROPOSED MOLECULAR CLASSIFICATION OF ACUTE MYELOBLASTIC LEUKEMIA (AML) BASED ON SPLICING EVENTS
Liquori, A.; (...); Cervera Zamora, J.
Meeting Abstract. 2021
Prostaglandin Injection After Arterial Compromise Related to Hyaluronic Acid Filler
Megias-Vericat, JE; (...); Poveda, JL
Letter. 10.1097/DSS.0000000000001046. 2017
Púrpura trombocitopénica trombótica inmune: sospecha y manejo básico en los servicios de urgencias. Revisión y consenso de un grupo de expertos de las sociedades científicas SEHH y SEMES.
Pascual-Izquierdo, Cristina; (...); de la Rubia Comos, Javier
Article. 10.55633/s3me/E099.2023. 2023
QUANTIFICATION OF CIRCULATING TUMOR CELLS IS THE MOST RELEVANT PROGNOSTIC FACTOR AT DIAGNOSIS IN PATIENTS WITH MULTIPLE MYELOMA, WHO ARE TRANSPLANT CANDIDATES, Abstracts
Juan-Jose, Garces; (...); Bruno, Paiva
Meeting Abstract. 2021
Quantification of physical activity in adult patients with haemophilic arthropathy in prophylaxis treatment using a fitness tracker
Perez-Alenda, S; (...); Querol, F
Letter. 10.1111/hae.13388. 2018
Real world evaluation of teclistamab in patients with RRMM: results from the IMF immunotherapy database project
Costa, Luciano; (...); Wong, Sandy
Meeting Abstract. 2023
Real-life clinical practice in Spain in the setting of new drug availability for ITP treatment. A Delphi-based Spanish expert panel consensus.
Gonzalez-Lopez, Tomas Jose; (...); Jarque, Isidro
Article. 10.1080/09537104.2024.2336104. 2024
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).
Abrisqueta, Pau; (...); Villanueva, Miguel
Article. 10.1016/j.clml.2021.07.022. 2021
Real-world effectiveness of caplacizumab vs standard of care in immune thrombotic thrombocytopenic purpura.
Pascual Izquierdo, Maria Cristina; (...); Del Rio-Garma, Julio
Article. 10.1182/bloodadvances.2022008028. 2022
Real-World Experience in Extracorporeal photopheresisfor adults with graft-versus-host disease.
Asensi Cantó P; (...); Gómez-Seguí I
Article. 10.1016/j.jtct.2023.09.001. 2023
Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI).
Mingot-Castellano, Maria Eva; (...); Pascual-Izquierdo, Cristina
Article. 10.3390/jcm12206422. 2023
Recommendations for the diagnosis and treatment of patients with thrombotic thrombocytopenic purpura.
Mingot Castellano, Maria Eva; (...); Grp Espanol Aferesis GEA
Practice Guideline. 10.1016/j.medcli.2021.03.040. 2022
Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part I: update on laboratory tests for the study of monoclonal gammopathies.
Cardenas, Maria C.; (...); Cruz-Iglesias, Elena
Article. 10.1515/cclm-2023-0326. 2023
Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part II: methodological and clinical recommendations for the diagnosis and follow-up of monoclonal gammopathies
Cardenas, Maria C.; (...); Cruz-Iglesias, Elena
Article. 10.1515/cclm-2023-0325. 2023
Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease
Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro
Meeting Abstract. 10.1182/blood-2022-167247. 2022
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.
Lakhwani S; (...); Hernández MT
Article. 10.3324/haematol.2023.284154. 2024
REDEFINING OUTCOMES IN IMMUNE TTP: AN INTERNATIONAL WORKING GROUP CONSENSUS REPORT.
Cuker A; (...); Scully M
Article. 10.1182/blood.2020009150. 2021
Reduced incidence of neurologic complications after allogeneic hematopoietic stem cell transplantation with calcineurin-free graft-versus-host disease prophylaxis.
Balaguer-Rosello, Aitana; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2023.07.008. 2023
Reduction in alert fatigue in an assisted electronic prescribing system, through the Lean Six Sigma methodology.
Cuéllar Monreal MJ; (...); Poveda Andrés JL
Article. 10.7399/fh.2017.41.1.10434. 2017
Relevancia de la anfotericina B liposomal en el tratamiento de las infecciones fúngicas invasoras en pacientes oncohematológicos.
García-Vidal C, Vázquez L, Jarque I
Article. 10.1016/j.riam.2021.03.001. 2021
Renal response to rescue treatments in Relapsed Refractory Multiple Myeloma (RRMM) patients with renal impairment: final data of a large, observational, prospective study (MIR50)
Garcia-Guinon, Antonio; (...); de la Rubia, Javier
Meeting Abstract. 2021
Results of the Ebmt Saawp Phase III Prospective Randomized Multicenter Race Study of Horse Atg and Ciclosporin with or Without Eltrombopag in Naive Saa Patients
de Latour, RP; (...); Risitano, A
Meeting Abstract. 2020
RESULTS OF THE PEGASUS PHASE III TRIAL FOR THE COMPARISON OF PEGCETACOPLAN WITH ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Jarque, Isidro; (...); Peffault, de latour Regis
Meeting Abstract. 2020
RETROSPECTIVE CONTROL CASE STUDY ON THE EFFICACY OF AUTOLOGOUS TRANSPLANTATION OF HAEMATOPOIETIC PROGENITORS IN THE FIRST LINE TREATMENT OF PATIENTS WITH PERIPHERAL T CELL LYMPHOMA
Parra, ML; (...); Martin, A. A.
Meeting Abstract. 2017
Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia
Robak, Tadeusz; (...); Jolles, Stephen
Meeting Abstract. 10.1182/blood-2019-129839. 2019
Salvage therapy with topical posaconazole in lung transplant recipients with invasive Scedosporium infection.
Article. 10.1111/ajt.14580. 2018
Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry
Jimenez-Ubieto, A; (...); Lahuerta, JJ
Letter. 10.1038/s41409-018-0096-6. 2018
Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option
Roman, E; (...); Gorriz, JL
Review. 10.1016/j.nefro.2017.01.006. 2017
SEFH National Survey-2019: general characteristics, staffing, material resources and information systems in Spain's hospital pharmacy departments.
Pérez-Encinas M; (...); Calleja-Hernández MÁ
Article. 10.7399/fh.11565. 2020
Selective IgA Deficiency and Blood Component Transfusion: In Search of the Lost Evidence
Solves, Pilar; (...); de la Rubia, Javier
Article. 10.3390/hemato5020009. 2024
SEQUENCING OF THE EXOME IN THE RECALLING OR REFRACTORY AML
Simarro Claudia, Sargas; (...); Eva, Barragan
Meeting Abstract. 2021
Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice
Aguas Peris M; (...); Nos, P
Article. 10.1097/MIB.0000000000001182. 2017
Serum adalimumab levels predict successful remission and safe de-intensification in inflammatory bowel disease patients in clinical practice
Meeting Abstract. 2017
Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic
Martinez-Lopez, Joaquin; (...); San-Miguel, Jesus F.
Meeting Abstract. 10.1182/blood-2021-149192. 2021
Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons.
Seguí IG; (...); de la Rubia J
Article. 10.1080/17474086.2024.2318347. 2024
SINGLE CELL-LEVEL CHARACTERIZATION OF THE IMMUNE MICROENVIRONMENT OF MULTIPLE MYELOMA IDENTIFIES CD27 NEGATIVE T LYMPHOCYTES AS TUMOR SPECIFIC
Perez, Cristina; (...); Paiva, Bruno
Meeting Abstract. 2020
Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics: a retrospective study of the PETHEMA/Spanish Myeloma Group (GEM)
Villalba, Ana; (...); De la Rubia, Javier
Meeting Abstract. 2022
Single-Cell Characterization of Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-negative T cells as Potential Tumor-Reactive Lymphocytes
Botta, C; (...); Paiva, B
Meeting Abstract. 10.1016/j.clml.2019.09.581. 2019
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial.
Puig N; (...); Mateos MV
Article. 10.3324/haematol.2024.285742. 2024
SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization
Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis
Article. 10.1111/jcpt.13703. 2022
Spanish Consensus on the Prevention and Treatment of Pseudomonas aeruginosa Bronchial Infections in Cystic Fibrosis Patients
Cantón R; (...); Solé A
Article. 10.1016/j.arbres.2014.09.021. 2015
Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria
Villegas A; (...); Urbano-Ispizua Á
Editorial Material. 10.1016/j.medcli.2015.12.012. 2016
Spanish National Registry of Celiac Disease: Incidence and Clinical Presentation
Cilleruelo ML; (...); Ribes-Koninckx C
Article. 10.1097/MPG.0000000000000446. 2014
Study on the Linezolid Prescription According to the Approval of Indication in a University Hospital
Pérez-Cebrián M; (...); Llopis-González A
Article. 2015
Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia
González-López TJ; (...); González-Porras JR
Article. 10.1002/ajh.23900. 2015
Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease
Lakhwani, Sunil; (...); Teodoro Hernandez Garcia, Miguel
Meeting Abstract. 10.1182/blood-2023-179452. 2023
Syncope as a manifestation of mast cell activation disorder
Perales Chordá C; (...); Hernández Fernandez de Rojas D
Letter. 10.1016/j.anai.2014.11.019. 2015
Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia
Megías-Vericat JE; (...); Montesinos P
Review. 10.3390/pharmaceutics14040878. 2022
T-cell Depleted Peripheral Blood versus Unmanipulated Bone Marrow in Matched Sibling Transplantation for Aplastic Anemia.
Chorao, Pedro; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2023.01.016. 2023
The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity
Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar
Article. 10.1007/s00431-022-04628-z. 2022
The Combined Immunohistochemical Expression of GLI1 and BCOR in Synovial Sarcomas for the Identification of Three Risk Groups and Their Prognostic Outcomes: A Study of 52 Patients.
Giner, Francisco; (...); Llombart-Bosch, Antonio
Article. 10.3390/ijms25147615. 2024
The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; (...); Gil A
Article. 10.1016/j.yebeh.2022.108711. 2022
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.
Medina-Herrera A; (...); Garcia-Sanz R
Article. 10.1038/s41408-024-01053-3. 2024
THE LASTING RESPONSE OF ELTROMBOPAG IN PRIMARY PTI IS A PREDICTOR FOR THE PROBABILITY OF DISCONTINUING THE SUCCESS OF ELTROMBOPAG
Porras, JRG; (...); Bastida, J. M.
Meeting Abstract. 2017
The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies
Strebel, Johanna A. Kremer Hovinga; (...); Scully, Marie
Meeting Abstract. 10.1182/blood-2022-156306. 2022
The Role of Immunohistochemistry in Rhabdomyosarcoma Diagnosis Using Tissue Microarray Technology and a Xenograft Model
Machado, I; (...); Llombart-Bosch, A
Article. 10.3109/15513815.2015.1042604. 2015
The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Badia, Xavier; (...); Valles, Joan-Antoni
Article. 10.1186/s13023-024-03324-5. 2024
The view of experts on initiatives to be undertaken to promote equity in the access to orphan drugs and specialised care for rare diseases in Spain: A Delphi consensus
Torrent-Farnell, J; (...); Lizan, L
Article. 10.1016/j.healthpol.2018.03.002. 2018
THROMBOTIC EVENTS IN PATIENTS WITH PTI TREATED WITH THROMBOPOIETIN RECEPTOR AGONISTS. IDENTIFICATION OF PREDISPOSING FACTORS
Lozano Almela, M. L.; (...); Vicente, V.
Meeting Abstract. 2019
Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule.
Marques MR; (...); Mangas-Sanjuan V
Article. 10.1111/apa.14944. 2020
Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy
Del Rio-Bermudez, C; (...); Poveda, JL
Editorial Material. 10.1186/s40545-020-00276-6. 2020
Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.
Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis
Article. 10.1136/ejhpharm-2024-004184. 2024
Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs.
Megías Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.rx.2015.01.008. 2015
Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single Institution.
Solves, Pilar; (...); Sanz, Jaime
Article. 10.3390/jcm12103467. 2023
Transfusion of ABO non-identical platelets does not influence the clinical outcome of patients undergoing autologous haematopoietic stem cell transplantation
Article. 10.2450/2015.0195-14. 2015
Treatment of invasive fungal disease using anidulafungin alone or in combination for hematologic patients with concomitant hepatic or renal impairment
Montesinos P; (...); Sanz MÁ
Article. 10.1016/j.riam.2014.10.003. 2015
Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma
Cejalvo, MJ; (...); de la Rubia, J
Article. 10.1007/s00277-021-04529-5. 2021
Undetectable levels of adalimumab in clinical practice: Should we say goodbye to the drug?
Bejar, S; (...); Mateu, PN
Meeting Abstract. 2020
Update of the Grupo Espanol de Leucemia Linfocitica Cronica clinical guidelines of the management of chronic lymphocytic leukemia
Garcia-Marco, JA; (...); Bosch, F
Editorial Material. 10.1016/j.medcli.2016.12.030. 2017
Use and handling safety of Mini-Spike 2 (R) chemo and puresite for safe chemotherapy compounding in a hospital pharmacy
Garcia, SV; (...); Andres, JLP
Article. 10.1016/j.yrtph.2018.10.002. 2018
Use of 2 hydroxypropyl-beta-cyclodextrin therapy in two adult Niemann Pick Type C patients
García-Robles AA; (...); Poveda JL
Letter. 10.1016/j.jns.2016.04.048. 2016
USE OF CAPLACIZUMAB IN THE ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
Dominguez Hernandez, L.; (...); Gomez Segui, I
Meeting Abstract. 2019
Use of eltrombopag after romiplostim in primary immune thrombocytopenia
González-Porras JR; (...); González-López TJ
Article. 10.1111/bjh.13266. 2015
Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia.
González-López TJ; (...); García-Frade LJ
Article. 10.1111/ejh.13370. 2020
Use of optical genome mapping in the cytogenetic diagnosis of multiple myeloma
de la Rubia, Javier; (...); Such, Esperanza
Meeting Abstract. 2023
Validation of a multivariable prediction model for post-engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients
Rodriguez-Veiga, Rebeca; (...); Sanz, Miguel A.
Article. 10.1111/myc.12891. 2019
Validation of a risk score for post-engraftment invasive fungal disease in 414 adult allogeneic hematopoietic stem cell transplant recipients
Montesinos, P.; (...); Sanz, M. A.
Meeting Abstract. 2016
VALIDATION OF FREQUENT SPLICING EVENTS IN ACUTE MYELOID LEUKEMIA WITH POTENTIAL TO GENERATE NEOANTIGENS
Beatriz, Fernandez-Blanco; (...); Jose Vicente, Cervera Zamora
Meeting Abstract. 2021
Validation of the IMWG standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?
Jimenez Ubieto, Ana; (...); Lahuerta, Juan-Jose
Article. 10.1182/blood.2021012319. 2021
Valor de la expresion inmunohistoquimica de alfa-metilacil-CoA racemasa en la progresion del carcinoma de colon.
Jessica Valdivia; (...); Ramos D
Article. 10.1016/j.patol.2016.04.003. 2017
VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA
Poveda, J. L.; (...); Lizan, L.
Meeting Abstract. 2023
VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study
Dachs, LR; (...); Blade, J
Meeting Abstract. 10.1182/blood-2018-99-111924. 2018
WHOLE GENE SEQUENCING FOR THE IDENTIFICATION OF SPLICING MUTATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
Mireya, Morote-Faubel; (...); Jose, Cervera
Meeting Abstract. 2021
WORKING SYSTEM DOCUMENTATION OF PROCEDURES AND INSTRUCTIONS FOR USE IN THE HEMATOLOGY DIAGNOSIS UNIT
Montalt, M.; (...); Sanz, M. A.
Meeting Abstract. 2015
Zoledronic acid as compared with observation in multiple myeioma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial
Garcia-Sanz, R; (...); Mateos, MV
Article. 10.3324/haematol.2015.128439. 2015